7 analysts' median target is $125[FMP target], stock is $89, +39.7% upside potential. After Q1 +0.9% EPS beat[FMP earnings], the stock moved +1.4%.
B = MoonshotScore 50[9-pillar formula] + Council 5/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q4 consensus: revenue $12.5B[FMP est], EPS $1.28[FMP est]. 1 consecutive quarters of beat[FMP earnings].
Q1 EPS +0.9% beat[FMP] but the stock +1.4% D+1[FMP D+1]. Philip Boudreau promised $399.0M CapEx + a sequential decline in Q4 during the Q1 earnings call[Philip Boudreau capex transcript].
Watchlist
Comparable Sales Growth Outlook
comparable_sales_growth_outlook
Abbott's full-year 2026 sales growth outlook is 6.5% to 7.5%, which includes the full-year sales of Exact Sciences.
"To align with our reporting of comparable sales growth, our full-year 2026 sales growth outlook of 6.5% to 7.5% is now on a comparable basis as well. The sales growth outlook includes the full-year sales of Exact Sciences in both the prior and current year."
- Philip Boudreau, Executive Vice President, Finance and Chief Financial Officer - Q1 FY26 Earnings Call - April 16, 2026
Electrophysiology Growth
electrophysiology_growth
Abbott expects growth in Electrophysiology, with 14% growth in the U.S. due to the launch of the Volt PFA catheter and double-digit growth in Europe due to the launch of the TactiFlex Duo catheter.
"In Electrophysiology, growth of 13% included contributions from two pulsed field ablation catheter launches in the quarter. The launch of our Volt PFA catheter contributed to growth of 14% in the U.S., and the launch of our TactiFlex Duo catheter helped drive mid-teens growth in Europe."
- Robert Ford, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - April 16, 2026
Earnings Per Share Dilution
earnings_per_share_dilution
Abbott's new guidance range midpoint of $5.48 for full-year adjusted earnings per share reflects $0.20 of dilution related to the Exact Sciences acquisition, compared to the previous guidance range midpoint of $5.68.
"Compared to our previous full-year adjusted earnings per share guidance range midpoint of $5.68, our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition, consistent with our assumption at the time of the announced transaction."
- Philip Boudreau, Executive Vice President, Finance and Chief Financial Officer - Q1 FY26 Earnings Call - April 16, 2026
Exact Sciences Acquisition
exact_sciences_acquisition
The acquisition of Exact Sciences is forecasted to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott Laboratories' long-term sales growth rate.
"As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott Laboratories' long-term sales growth rate."
- Robert Ford, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - April 16, 2026
Rhythm Management Outperformance
rhythm_management_outperformance
Abbott's Rhythm Management sales grew 13%, marking the third consecutive quarter of double-digit growth and continued outperforming the market significantly.
"In Rhythm Management, sales grew 13%, marking the third consecutive quarter that we have delivered double-digit growth and continued our track record of significantly outperforming the market."
- Robert Ford, Chairman and Chief Executive Officer - Q1 FY26 Earnings Call - April 16, 2026
Stock Expert AI - Methodology
9-pillar methodology. Cash Runway and News Sentiment strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 5 bullish (Ray Dalio, Jim Simons, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 0 neutral (none).
How is it calculated? ->Quality business, discounted price.
How is it calculated? ->Past Performance
Q1 (April 16, 2026): EPS $1.15 vs $1.14 est[FMP], +0.9% beat. D+1 movement: +1.4%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q1: EPS $1.15 vs $1.14 beat[FMP], stock +1.4% D+1[FMP].
No RPO/backlog concentration disclosed in Q1 earnings call.
Q1 CapEx $399.0M[FMP cashflow]. Q1 op margin 16.5%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $1.28[FMP], CapEx threshold "below $399.0M"[Philip Boudreau]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This ABT (ABT) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.